Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409240 · ClinicalTrials.gov registry record · Phase 3
Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes
A Phase 3 study, sponsored by Providence VA Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT00409240: Completed Phase 3 study, sponsored by Providence VA Medical Center.
NCT00409240 is a Phase 3 study that has completed, run by Providence VA Medical Center. The registered enrollment target is 103 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00409240, a Phase 3 study, has completed, sponsored by Providence VA Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
Our study intends to test the efficacy of pharmacist-led group interventions on a weekly basis for 4-weeks, then on a monthly basis for 5 additional months to achieve concomitant reductions in hemoglobin A1c, lipids and blood pressure.
Primary Outcome
Hemoglobin A1C target was \< 7% LDL cholesterol goal of \< 100mg/dl or \<70mg/dl for patients at high risk-current cardiovascular disease Systolic blood pressure goal of \<130mm Hg
Interventions
- OTHER MEDIC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00409240 record still lists
NCT00409240 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which MEDIC is the first listed.
NCT00409240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00409240 about?
NCT00409240 is a clinical study titled "Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes". Our study intends to test the efficacy of pharmacist-led group interventions on a weekly basis for 4-weeks, then on a monthly basis for 5 additional months to achieve concomitant reductions in hemoglobin A1c, lipids and blood pressure.
What is the current status of trial NCT00409240?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2006-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00409240?
The interventions under investigation include: MEDIC (OTHER).
Who is sponsoring clinical trial NCT00409240?
This trial is sponsored by Providence VA Medical Center, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00409240's enrollment target sits among peer trials
103 1674th of 2000 higher than 325 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia